These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 36630992)
1. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992 [TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Dall'Olio FG; Gelsomino F; Conci N; Marcolin L; De Giglio A; Grilli G; Sperandi F; Fontana F; Terracciano M; Fragomeno B; Tober N; Manferrari G; Brocchi S; Golfieri R; Fiorentino M; Ardizzoni A Clin Lung Cancer; 2021 Sep; 22(5):423-431. PubMed ID: 33849808 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis. Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578 [TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741 [TBL] [Abstract][Full Text] [Related]
5. Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor. Kennedy LC; Lu J; Kuehn S; Ramirez AB; Lo E; Sun Y; U'Ren L; Chow LQM; Chen Z; Grivas P; Kaldjian EP; Gadi VK Target Oncol; 2022 May; 17(3):329-341. PubMed ID: 35696014 [TBL] [Abstract][Full Text] [Related]
6. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729 [TBL] [Abstract][Full Text] [Related]
7. Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy. Zhou Y; Zhou J; Hao X; Shi H; Li X; Wang A; Hu Z; Yang Y; Jiang Z; Wang T Breast Cancer Res Treat; 2023 Jul; 200(2):281-291. PubMed ID: 37227611 [TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer. Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004 [TBL] [Abstract][Full Text] [Related]
10. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135 [TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC. Kloten V; Lampignano R; Krahn T; Schlange T Cells; 2019 Aug; 8(8):. PubMed ID: 31374957 [TBL] [Abstract][Full Text] [Related]
12. Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab. Spiliotaki M; Neophytou CM; Vogazianos P; Stylianou I; Gregoriou G; Constantinou AI; Deltas C; Charalambous H Mol Oncol; 2023 May; 17(5):792-809. PubMed ID: 36177552 [TBL] [Abstract][Full Text] [Related]
13. Meta-Analysis of Circulating Tumor Cell PD-L1 Expression and the Association with Clinical Outcomes in Non-Small Cell Lung Cancer. Acheampong E; Allsopp RC; Page K; Wadsley MK; Beasley AB; Coombes RC; Shaw JA; Gray ES Clin Chem; 2024 Jan; 70(1):234-249. PubMed ID: 38175603 [TBL] [Abstract][Full Text] [Related]
14. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391 [TBL] [Abstract][Full Text] [Related]
15. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors]. Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798 [No Abstract] [Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
17. Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12. Xu Y; Ding L; Li H; Peng Z; Ding K; Huang Z; Zhou Z; Xie M; Yan J; Feng S; Fan Y Front Immunol; 2023; 14():1194123. PubMed ID: 37359565 [TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821 [TBL] [Abstract][Full Text] [Related]
19. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer. Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757 [TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. Kulasinghe A; Kapeleris J; Kimberley R; Mattarollo SR; Thompson EW; Thiery JP; Kenny L; O'Byrne K; Punyadeera C Cancer Med; 2018 Dec; 7(12):5910-5919. PubMed ID: 30565869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]